Retraction Note: Naunyn-Schmiedeberg's Arch Pharmacol
The Editor in Chief has retracted this article (Wang et al., 2020). After publication concerns were raised about anomalies in some of the data presented in Figs. 4 and 5. The authors have been given the opportunity to submit a new manuscript for peer review.
Author Yingwei Zhang agreed to retraction but has not stated if they agree to this retraction notice. The remaining authors did not respond to any correspondence from the editor or publisher about this retraction.
Reference
Wang C, Chang R, Gao G, Liu X, Zhang Y (2020) Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation. Naunyn Schmiedeberg's Arch Pharmacol 393:1515–1525. https://doi.org/10.1007/s00210-019-01770-8
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s00210-019-01770-8
About this article
Cite this article
Wang, C., Chang, R., Gao, G. et al. Retraction Note: Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation. Naunyn-Schmiedeberg's Arch Pharmacol 394, 573 (2021). https://doi.org/10.1007/s00210-020-02027-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-020-02027-5